Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 6 studies | 25% ± 9% | |
oligodendrocyte precursor cell | 4 studies | 32% ± 13% | |
endothelial cell | 3 studies | 20% ± 4% |
Insufficient scRNA-seq data for expression of CHST3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 4449.39 | 258 / 258 | 97% | 18.92 | 224 / 230 |
skin | 100% | 3357.72 | 1805 / 1809 | 97% | 30.15 | 459 / 472 |
thymus | 99% | 2010.99 | 645 / 653 | 97% | 15.54 | 585 / 605 |
kidney | 100% | 2433.46 | 89 / 89 | 93% | 21.41 | 837 / 901 |
uterus | 100% | 5023.49 | 170 / 170 | 92% | 18.91 | 421 / 459 |
esophagus | 99% | 3359.35 | 1430 / 1445 | 89% | 26.08 | 163 / 183 |
lung | 99% | 2763.49 | 573 / 578 | 85% | 17.90 | 979 / 1155 |
breast | 100% | 4068.13 | 459 / 459 | 84% | 14.44 | 937 / 1118 |
prostate | 99% | 4061.39 | 243 / 245 | 84% | 10.27 | 421 / 502 |
brain | 78% | 1520.71 | 2066 / 2642 | 100% | 40.17 | 704 / 705 |
ovary | 100% | 6828.68 | 180 / 180 | 73% | 9.81 | 316 / 430 |
bladder | 100% | 3330.29 | 21 / 21 | 62% | 9.08 | 311 / 504 |
stomach | 99% | 3988.38 | 356 / 359 | 60% | 7.03 | 171 / 286 |
pancreas | 53% | 623.13 | 174 / 328 | 93% | 17.86 | 165 / 178 |
intestine | 87% | 2879.77 | 843 / 966 | 56% | 6.70 | 296 / 527 |
adipose | 100% | 4211.97 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7588.21 | 1335 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 32.79 | 44 / 45 |
heart | 96% | 3234.20 | 827 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 12.79 | 76 / 80 |
muscle | 94% | 3428.00 | 751 / 803 | 0% | 0 | 0 / 0 |
spleen | 58% | 660.31 | 140 / 241 | 0% | 0 | 0 / 0 |
liver | 4% | 53.79 | 10 / 226 | 21% | 3.80 | 84 / 406 |
lymph node | 0% | 0 | 0 / 0 | 14% | 0.79 | 4 / 29 |
peripheral blood | 1% | 6.52 | 6 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0043029 | Biological process | T cell homeostasis |
GO_0005975 | Biological process | carbohydrate metabolic process |
GO_0006044 | Biological process | N-acetylglucosamine metabolic process |
GO_0030206 | Biological process | chondroitin sulfate biosynthetic process |
GO_0006790 | Biological process | sulfur compound metabolic process |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0000139 | Cellular component | Golgi membrane |
GO_0008459 | Molecular function | chondroitin 6-sulfotransferase activity |
GO_0050698 | Molecular function | proteoglycan sulfotransferase activity |
GO_0001517 | Molecular function | N-acetylglucosamine 6-O-sulfotransferase activity |
Gene name | CHST3 |
Protein name | Carbohydrate sulfotransferase 3 (EC 2.8.2.17) (EC 2.8.2.21) (Chondroitin 6-O-sulfotransferase 1) (C6ST-1) (Chondroitin 6-sulfotransferase) (C6ST) (Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 0) (GST-0) |
Synonyms | |
Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of the N-acetylgalactosamine (GalNAc) residue of chondroitin . Chondroitin sulfate constitutes the predominant proteoglycan present in cartilage and is distributed on the surfaces of many cells and extracellular matrices . Catalyzes with a lower efficiency the sulfation of Gal residues of keratan sulfate, another glycosaminoglycan . Can also catalyze the sulfation of the Gal residues in sialyl N-acetyllactosamine (sialyl LacNAc) oligosaccharides (By similarity). May play a role in the maintenance of naive T-lymphocytes in the spleen (By similarity). . |
Accessions | Q7LGC8 ENST00000373115.5 |